The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has enrolled 1513 patients and is expected to continue for 3.5 years after the last patient has been entered. Eligible patients mu...

Full description

Bibliographic Details
Main Authors: Barry M Brenner, Mark E Cooper, Dick de Zeeuw, Jean-Pierre Grunfeld, William F Keane, Kiyoshi Kurokawa, Janet B McGill, William E Mitch, Hans Henrik Parving, Guiseppe Remuzzi, Arthur B Ribeiro, Mark D Schluchter, Duane Snavely, Zhongxin Zhang, Roger Simpson, Denise Ramjit, Shahnaz Shahinfar, RENAAL Study Investigators
Format: Article
Language:English
Published: SAGE Publications 2000-12-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.3317/jraas.2000.062

Internet

https://doi.org/10.3317/jraas.2000.062

Similar Items